Translate Bio Inc.

BioCentury’s latest Venture Report also features news about LoQus23, Aktis, Resolution, Triveni, Flagship and more

Also in BioCentury’s weekly Public Equity Report: Ascendis follows up a data release with a $300M offering; BioAge proposes terms for listing

Plus: Matthieu Coutet joins Sofinnova Partners, and updates from Vanqua Bio, Adela, Velia and more

Again investing outside immunology, pharma sees differentiation in potential competitor with Karuna’s registrational schizophrenia therapy

On heels of ImmunoGen deal, pharma looks to Pfizer spinout led by Coles, Renaud to add neuroscience candidates nearing clinical readouts

Plus: Burgess to head BD at Cerevel, and updates from Mablink, PathAI and Berlin

Ahead of handful of milestones, former Translate Bio, Idenix CEO joining CNS company; Coles retaining chairman role

ATP’s $50M series A will help advance a lead ophthalmic program

Plus BMS’s new pricing SVP and updates from Forbion, Nuvalent and more

Plus Melton rejoining Sanna at Vertex and updates from CARsgen, Third Harmonic and more